A Phase 4 interventional study of Xeomin® in Cervical Dystonia, sponsored by Merz Pharmaceuticals GmbH. Completed at 43 sites in United States. Open to participants aged 18 Years to 81 Years. Per ClinicalTrials.gov, last updated 2022-10-27.
Sponsored by Merz Pharmaceuticals GmbH · Phase 4, Interventional, and Treatment
This study will compare Xeomin®, a botulinum toxin medication, in shorter treatment intervals (Short Flex dosing) to the standard interval dosing (Long Flex dosing) to determine if the response to treatment is comparable in both how it works and any side effects. Xeomin® is approved by the United States Food and Drug Administration (FDA) for the treatment of cervical dystonia (CD). The use of Xeomin® is investigational in regards to shorter treatment intervals. An investigational use is one that is not approved by the FDA.
Dystonia is a movement disorder which is characterized by sustained, involuntary muscle contractions which frequently causes twisting and repetitive movements or abnormal postures of the trunk, neck, face, or arms and legs. In focal dystonia, the abnormal movements involve a single area of the body. A commonly described form of focal dystonia is cervical dystonia (CD). Botulinum toxin treatment can be offered as a treatment option for the treatment of CD.
The current practice for botulinum toxin injection treatment is to inject patients every 3 months. However, not all patients receive continuing benefit from botulinum toxin injections for an entire 3 months. In a recent survey, approximately 45% of patients report that they would prefer a treatment cycle of less than 10 weeks.This study will compare Xeomin®, a botulinum toxin treatment, in shorter treatment intervals (Short Flex dosing) to the standard interval dosing (Long Flex dosing) to determine if the response to treatment is comparable in both how it works and any side effects. Xeomin® is approved by the United States Food and Drug Administration (FDA) for the treatment of CD. The use of Xeomin® is investigational in regards to shorter treatment intervals. An investigational use is one that is not approved by the FDA.
The purpose of this research study is to evaluate the efficacy of the Short Flex dosing of Xeomin® compared to the Long Flex dosing regimen of Xeomin®, using a standard scale completed by the doctors and subjects as well as questionnaires that ask subjects to rate symptoms of CD.
319 studies on the registry are indexed under Dystonia; 56 are open to participants now.
This study's enrollment of 283 is above the median of 32 across 181 interventional studies indexed under Dystonia.
Browse Dystonia studies →Merz Pharmaceuticals GmbH is the lead sponsor of 60 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
short flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
Biological: Xeomin®
long flex dosing of Xeomin. It is a botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A.
Biological: Xeomin®
Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
Also known as: botulinum toxin, botulinum toxin type A
Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Severity Subscale Score Based on Blinded Rater Assessment at Week 4 After the 8th Injection
The validated assessment scale TWSTRS was used to measure the impact of cervical dystonia (CD) on participants. A blinded rater performed all TWSTRS-Severity subscale assessments for a given participant. TWSTRS-Severity subscale score ranges from 0 (=absence of severity) to 35 points (=maximum severity).
Time frame: Baseline and Week 4 after the 8th injection (Week 44 to 68 for Short Flex and Week 84 to 104 for Long Flex)
Change From Baseline in TWSTRS Total Score Based on Blinded Rater Assessment at Week 4 After the 8th Injection
The validated assessment scale TWSTRS was used to measure the impact of CD on participants. The scale comprised of 3 subscales: Severity, Disability, and Pain, each of which was scored independently. A blinded rater performed all TWSTRS assessments for a given participant. TWSTRS-Severity subscale score ranges from 0 (=absence of severity) to 35 points (=maximum severity); TWSTRS-Disability subscale score ranges from 0 (no disability) to 30 (maximum disability); and TWSTRS-Pain subscale score ranges from 0 (no pain) to 20 (maximum pain). The total of these 3 comprises the TWSTRS total score which is scored from 0 (no symptoms) to 85 (worst symptoms). Higher scores indicate a greater impact of CD on participant.
Time frame: Baseline and Week 4 after the 8th injection (Week 44 to 68 for Short Flex and Week 84 to 104 for Long Flex)
Change From Baseline in TWSTRS Total Score Based on Unblinded Rater Assessment at Week 4 After the 8th Injection
The validated assessment scale TWSTRS was used to measure the impact of CD on participant. The scale comprised of 3 subscales: Severity, Disability, and Pain, each of which was scored independently. An unblinded rater performed all TWSTRS assessments for a given participant. TWSTRS-Severity subscale score ranges from 0 (=absence of severity) to 35 points (=maximum severity); TWSTRS-Disability subscale score ranges from 0 (no disability) to 30 (maximum disability); and TWSTRS-Pain subscale score ranges from 0 (no pain) to 20 (maximum pain). The total of these 3 comprises the TWSTRS total score which is scored from 0 (least symptoms) to 85 (worst symptoms). Higher scores indicate a greater impact of CD on participant.
Time frame: Baseline and Week 4 after the 8th injection (Week 44 to 68 for Short Flex and Week 84 to 104 for Long Flex)
Change From Baseline in TWSTRS Severity Subscale Based on Unblinded Rater Assessment at Week 4 After the 8th Injection
The validated assessment scale TWSTRS was used to measure the impact of cervical dystonia (CD) on participants. An unblinded rater performed all TWSTRS-Severity subscale assessments for a given participant. TWSTRS-Severity score ranges from 0 (absence of severity) to 35 (maximum severity).
Time frame: Baseline and Week 4 after the 8th injection (Week 44 to 68 for Short Flex and Week 84 to 104 for Long Flex)
Change From Baseline in TWSTRS Disability Subscale Based on Unblinded Rater Assessment at Week 4 After the 8th Injection
The validated assessment scale TWSTRS was used to measure the impact of CD on participant. An unblinded rater performed all TWSTRS-Disability subscale assessments for a given participant. TWSTRS-Disability score ranges from 0 (no disability) to 30 (maximum disability).
Time frame: Baseline and Week 4 after the 8th injection (Week 44 to 68 for Short Flex and Week 84 to 104 for Long Flex)
Change From Baseline in TWSTRS Pain Subscale Based on Unblinded Rater Assessment at Week 4 After the 8th Injection
The validated assessment scale TWSTRS was used to measure the impact of CD on participants. An unblinded rater performed all TWSTRS-Pain subscale assessments for a given participant. TWSTRS-Pain score ranges from 0 (no pain) to 20 (maximum pain).
Time frame: Baseline and Week 4 after the 8th injection (Week 44 to 68 for Short Flex and Week 84 to 104 for Long Flex)
Change From Control Visit Week 4 After First Injection in Investigator-Rated Global Response at Week 4 After the 8th Injection
The Investigator-Rated Global Response assessment for each Xeomin treatment was scored using a 9-point scale with a score ranging from -4 to +4 as follows: -4 (very marked worsening); -3 (marked worsening); -2 (moderately worsening); 1 (minimally worsening); 0 (no change); +1 (minimally improved); +2 (moderately improved); +3 (significantly improved); +4 (complete abolishment of signs and symptoms).
Time frame: Week 4 and Week 4 after the 8th injection (Week 44 to 68 for Short Flex and Week 84 to 104 for Long Flex)
Change From Control Visit Week 4 After First Injection in Subject-Rated Global Response at Week 4 After the 8th Injection
The Subject-Rated Global Response assessment for each Xeomin treatment was scored using a 9-point scale with a score ranging from -4 to +4 as follows: -4 (very marked worsening); -3 (marked worsening); -2 (moderately worsening); 1 (minimally worsening); 0 (no change); +1 (minimally improved); +2 (moderately improved); +3 (significantly improved); +4 (complete abolishment of signs and symptoms).
Time frame: Week 4 and Week 4 after the 8th injection (Week 44 to 68 for Short Flex and Week 84 to 104 for Long Flex)
Change From Control Visit Week 4 After First Injection in Subject Satisfaction Score at Week 4 After the 8th Injection
The Subject Satisfaction assessment for each Xeomin treatment was scored using a 10-point scale to answer the question, "How satisfied are you at the moment with your current therapy? Score ranges from: 1 (completely satisfied) to 10 (completely unsatisfied).
Time frame: Week 4 and Week 4 after the 8th injection (Week 44 to 68 for Short Flex and Week 84 to 104 for Long Flex)
Change From Baseline in Clinical Global Impression-Severity
Assessment of Clinical Global Impression Severity was scored using a 7-point scale for severity of illness, in response to the question, "Considering your total clinical experience with this particular population, how ill is the participant at this time?" With scores as: 0 (not assessed); 1 (normal, not ill at all); 2 (borderline ill); 3 (mildly ill); 4 (moderately ill); 5 (markedly ill); 6 (severely ill); and 7 (among the most extremely ill participants).
Time frame: Baseline and 8th injection (Week 44 for Short Flex and Week 84 for Long Flex)
Change From Baseline in Cervical Dystonia Impact Profile-58 (CDIP-58) Total Score at Week 4 After the 8th Injection
The CDIP-58 assesses the health impact of CD. The CDIP-58 is composed of eight domains: head and neck (6 items; 6 to 30 points), pain and discomfort (5 items; 5 to 25 points), upper limb activities (9 items; 9 to 45 points), walking (9 items; 9 to 45 points), sleep (4 items; 4 to 20 points), annoyance (8 items; 8 to 40 points), mood (7 items; 7 to 35 points), and psychosocial functioning (10 items; 10 to 50 points). Subscale scores were transformed to a common theoretical range of 0 (no impact) to 100 (most impact). Transformation to a 0 to 100 scale for the sum scores of the sub- and total scales were done using the following formula (all single items have scores from 1 to 5): S0 to 100 =25 \* (\[ SO / NI\] - 1), S0 to 100 = transformed sum score. SO = sum score of the original sub- / total scale. NI = number of items in the sub- / total scale. Negative changes from the baseline total score indicate improvement in the impact of CD on health whereas positive changes indicate worsening.
Time frame: Baseline and Week 4 after the 8th injection (Week 44 to 68 for Short Flex and Week 84 to 104 for Long Flex)
Change From Baseline in CDIP-58 Subscales' Scores at Week 4 After the 8th Injection
The CDIP-58 assesses the health impact of CD. The CDIP-58 is composed of eight domains: head and neck (6 items; 6 to 30 points), pain and discomfort (5 items; 5 to 25 points), upper limb activities (9 items; 9 to 45 points), walking (9 items; 9 to 45 points), sleep (4 items; 4 to 20 points), annoyance (8 items; 8 to 40 points), mood (7 items; 7 to 35 points), and psychosocial functioning (10 items; 10 to 50 points). Subscale scores were transformed to a common theoretical range of 0 (no impact) to 100 (most impact). Negative changes from the baseline scores indicate improvement in the impact of CD on health whereas positive changes indicate worsening.
Time frame: Baseline and Week 4 after the 8th injection (Week 44 to 68 for Short Flex and Week 84 to 104 for Long Flex)
Time to Offset of Xeomin Effects by Injection Cycle
The Offset Questionnaire was a single question: "On most days last week, have you noticed that your CD symptoms are better, worse or the same as the week prior? Time to offset of effect was calculated from date of first onset of effect to date of offset of effects.
Time frame: Week 4 up to Week 112
The study was conducted at 43 sites in the United States.
| Milestone | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Started | 142 | 141 |
| Treated | 142 | 140 |
| Completed | 113 | 94 |
| Not completed | 29 | 47 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Adverse event | 3 | 3 |
| Withdrew: Lack of efficacy | 6 | 10 |
| Withdrew: Withdrawal by subject | 7 | 18 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Protocol violation | 3 | 0 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Other | 5 | 11 |
| Withdrew: Not treated | 0 | 1 |
The validated assessment scale TWSTRS was used to measure the impact of cervical dystonia (CD) on participants. A blinded rater performed all TWSTRS-Severity subscale assessments for a given participant. TWSTRS-Severity subscale score ranges from 0 (=absence of severity) to 35 points (=maximum severity).
| score on a scale | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Severity Subscale Score Based on Blinded Rater Assessment at Week 4 After the 8th Injection | -4.1 ± 5.5 | -2.4 ± 5.4 |
The validated assessment scale TWSTRS was used to measure the impact of CD on participants. The scale comprised of 3 subscales: Severity, Disability, and Pain, each of which was scored independently. A blinded rater performed all TWSTRS assessments for a given participant. TWSTRS-Severity subscale score ranges from 0 (=absence of severity) to 35 points (=maximum severity); TWSTRS-Disability subscale score ranges from 0 (no disability) to 30 (maximum disability); and TWSTRS-Pain subscale score ranges from 0 (no pain) to 20 (maximum pain). The total of these 3 comprises the TWSTRS total score which is scored from 0 (no symptoms) to 85 (worst symptoms). Higher scores indicate a greater impact of CD on participant.
| score on a scale | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Change From Baseline in TWSTRS Total Score Based on Blinded Rater Assessment at Week 4 After the 8th Injection | -8.5 ± 10.3 | -7.6 ± 11.0 |
The validated assessment scale TWSTRS was used to measure the impact of CD on participant. The scale comprised of 3 subscales: Severity, Disability, and Pain, each of which was scored independently. An unblinded rater performed all TWSTRS assessments for a given participant. TWSTRS-Severity subscale score ranges from 0 (=absence of severity) to 35 points (=maximum severity); TWSTRS-Disability subscale score ranges from 0 (no disability) to 30 (maximum disability); and TWSTRS-Pain subscale score ranges from 0 (no pain) to 20 (maximum pain). The total of these 3 comprises the TWSTRS total score which is scored from 0 (least symptoms) to 85 (worst symptoms). Higher scores indicate a greater impact of CD on participant.
| score on a scale | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Change From Baseline in TWSTRS Total Score Based on Unblinded Rater Assessment at Week 4 After the 8th Injection | -9.4 ± 11.1 | -10.3 ± 10.9 |
The validated assessment scale TWSTRS was used to measure the impact of cervical dystonia (CD) on participants. An unblinded rater performed all TWSTRS-Severity subscale assessments for a given participant. TWSTRS-Severity score ranges from 0 (absence of severity) to 35 (maximum severity).
| score on a scale | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Change From Baseline in TWSTRS Severity Subscale Based on Unblinded Rater Assessment at Week 4 After the 8th Injection | -4.8 ± 6.2 | -5.1 ± 4.9 |
The validated assessment scale TWSTRS was used to measure the impact of CD on participant. An unblinded rater performed all TWSTRS-Disability subscale assessments for a given participant. TWSTRS-Disability score ranges from 0 (no disability) to 30 (maximum disability).
| score on a scale | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Change From Baseline in TWSTRS Disability Subscale Based on Unblinded Rater Assessment at Week 4 After the 8th Injection | -1.9 ± 4.5 | -2.1 ± 5.8 |
The validated assessment scale TWSTRS was used to measure the impact of CD on participants. An unblinded rater performed all TWSTRS-Pain subscale assessments for a given participant. TWSTRS-Pain score ranges from 0 (no pain) to 20 (maximum pain).
| score on a scale | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Change From Baseline in TWSTRS Pain Subscale Based on Unblinded Rater Assessment at Week 4 After the 8th Injection | -2.7 ± 4.2 | -3.1 ± 4.9 |
The Investigator-Rated Global Response assessment for each Xeomin treatment was scored using a 9-point scale with a score ranging from -4 to +4 as follows: -4 (very marked worsening); -3 (marked worsening); -2 (moderately worsening); 1 (minimally worsening); 0 (no change); +1 (minimally improved); +2 (moderately improved); +3 (significantly improved); +4 (complete abolishment of signs and symptoms).
| score on a scale | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Change From Control Visit Week 4 After First Injection in Investigator-Rated Global Response at Week 4 After the 8th Injection | -0.3 ± 1.47 | -0.1 ± 1.45 |
The Subject-Rated Global Response assessment for each Xeomin treatment was scored using a 9-point scale with a score ranging from -4 to +4 as follows: -4 (very marked worsening); -3 (marked worsening); -2 (moderately worsening); 1 (minimally worsening); 0 (no change); +1 (minimally improved); +2 (moderately improved); +3 (significantly improved); +4 (complete abolishment of signs and symptoms).
| score on a scale | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Change From Control Visit Week 4 After First Injection in Subject-Rated Global Response at Week 4 After the 8th Injection | 0.4 ± 1.61 | 0.5 ± 1.79 |
The Subject Satisfaction assessment for each Xeomin treatment was scored using a 10-point scale to answer the question, "How satisfied are you at the moment with your current therapy? Score ranges from: 1 (completely satisfied) to 10 (completely unsatisfied).
| score on a scale | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Change From Control Visit Week 4 After First Injection in Subject Satisfaction Score at Week 4 After the 8th Injection | -1.2 ± 3.42 | -0.6 ± 3.42 |
Assessment of Clinical Global Impression Severity was scored using a 7-point scale for severity of illness, in response to the question, "Considering your total clinical experience with this particular population, how ill is the participant at this time?" With scores as: 0 (not assessed); 1 (normal, not ill at all); 2 (borderline ill); 3 (mildly ill); 4 (moderately ill); 5 (markedly ill); 6 (severely ill); and 7 (among the most extremely ill participants).
| score on a scale | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Change From Baseline in Clinical Global Impression-Severity | -0.5 ± 0.89 | -0.1 ± 1.03 |
The CDIP-58 assesses the health impact of CD. The CDIP-58 is composed of eight domains: head and neck (6 items; 6 to 30 points), pain and discomfort (5 items; 5 to 25 points), upper limb activities (9 items; 9 to 45 points), walking (9 items; 9 to 45 points), sleep (4 items; 4 to 20 points), annoyance (8 items; 8 to 40 points), mood (7 items; 7 to 35 points), and psychosocial functioning (10 items; 10 to 50 points). Subscale scores were transformed to a common theoretical range of 0 (no impact) to 100 (most impact). Transformation to a 0 to 100 scale for the sum scores of the sub- and total scales were done using the following formula (all single items have scores from 1 to 5): S0 to 100 =25 \* (\[ SO / NI\] - 1), S0 to 100 = transformed sum score. SO = sum score of the original sub- / total scale. NI = number of items in the sub- / total scale. Negative changes from the baseline total score indicate improvement in the impact of CD on health whereas positive changes indicate worsening.
| score on a scale | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Change From Baseline in Cervical Dystonia Impact Profile-58 (CDIP-58) Total Score at Week 4 After the 8th Injection | -14.42 ± 20.377 | -12.45 ± 18.457 |
The CDIP-58 assesses the health impact of CD. The CDIP-58 is composed of eight domains: head and neck (6 items; 6 to 30 points), pain and discomfort (5 items; 5 to 25 points), upper limb activities (9 items; 9 to 45 points), walking (9 items; 9 to 45 points), sleep (4 items; 4 to 20 points), annoyance (8 items; 8 to 40 points), mood (7 items; 7 to 35 points), and psychosocial functioning (10 items; 10 to 50 points). Subscale scores were transformed to a common theoretical range of 0 (no impact) to 100 (most impact). Negative changes from the baseline scores indicate improvement in the impact of CD on health whereas positive changes indicate worsening.
| score on a scale | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Head and neck score | -22.49 ± 24.699 | -23.70 ± 27.152 |
| Pain and discomfort score | -13.79 ± 27.912 | -7.92 ± 23.906 |
| Sleep score | -12.79 ± 29.045 | -9.97 ± 26.158 |
| Upper limb activities score | -8.98 ± 22.822 | -8.27 ± 20.982 |
| Walking score | 8.41 ± 809 | -7.01 ± 20.884 |
| Annoyance score | 15.83 ± 25.735 | -9.69 ± 24.771 |
| Mood score | -14.52 ± 24.307 | -10.20 ± 23.137 |
| Psychosocial functioning score | -15.90 ± 24.764 | -15.81 ± 23.428 |
The Offset Questionnaire was a single question: "On most days last week, have you noticed that your CD symptoms are better, worse or the same as the week prior? Time to offset of effect was calculated from date of first onset of effect to date of offset of effects.
| weeks | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| Injection 1 | 4.8 ± 2.85 | 5.8 ± 3.89 |
| Injection 2 | 4.8 ± 2.60 | 6.8 ± 3.83 |
| Injection 3 | 5.0 ± 2.31 | 7.8 ± 3.52 |
| Injection 4 | 5.1 ± 2.60 | 8.6 ± 3.70 |
| Injection 5 | 5.4 ± 3.00 | 9.2 ± 3.05 |
| Injection 6 | 6.4 ± 2.36 | 9.5 ± 2.50 |
| Injection 7 | 5.4 ± 2.63 | 9.1 ± 2.80 |
| Injection 8 | 4.2 ± 1.94 | — |
Collected over Baseline up to Day 875. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Xeomin Short Flex | 1/142 (0.7%) | 15/142 (10.6%) | 77/142 (54.2%) |
| Xeomin Long Flex | 1/140 (0.7%) | 11/140 (7.9%) | 77/140 (55%) |
| Event | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| NauseaGastrointestinal disorders | 0/142 | 2/140 |
| VomitingGastrointestinal disorders | 0/142 | 2/140 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/142 | 2/140 |
| SyncopeNervous system disorders | 2/142 | 0/140 |
| PneumoniaInfections and infestations | 1/142 | 1/140 |
| GastroenteritisInfections and infestations | 0/142 | 1/140 |
| SinusitisInfections and infestations | 0/142 | 1/140 |
| Urinary tract infectionInfections and infestations | 0/142 | 1/140 |
| Burning sensationNervous system disorders | 0/142 | 1/140 |
| Cerebral artery stenosisNervous system disorders | 0/142 | 1/140 |
| Event | Xeomin Short Flex | Xeomin Long Flex |
|---|---|---|
| DysphagiaGastrointestinal disorders | 36/142 | 35/140 |
| HeadacheNervous system disorders | 12/142 | 17/140 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 10/142 | 12/140 |
| Back painMusculoskeletal and connective tissue disorders | 5/142 | 10/140 |
| Neck painMusculoskeletal and connective tissue disorders | 9/142 | 9/140 |
| NauseaGastrointestinal disorders | 6/142 | 9/140 |
| Upper respiratory tract infectionInfections and infestations | 9/142 | 4/140 |
| FallInjury, poisoning and procedural complications | 8/142 | 7/140 |
| NasopharyngitisInfections and infestations | 8/142 | 4/140 |
| SinusitisInfections and infestations | 6/142 | 7/140 |
The safety evaluation set (SES) included all participants who were randomly assigned and received at least one study treatment, Xeomin Short-Flex or Long-Flex injection.
| Age, Continuous(years) | Xeomin Short Flex | Xeomin Long Flex | Total |
|---|---|---|---|
| Mean | 57.4 ± 10.62 | 56.7 ± 11.30 | 57.1 ± 10.95 |
| Sex: Female, Male(Participants) | Xeomin Short Flex | Xeomin Long Flex | Total |
|---|---|---|---|
| Female | 106 | 98 | 204 |
| Male | 36 | 42 | 78 |
| Race/Ethnicity, Customized(Participants) | Xeomin Short Flex | Xeomin Long Flex | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 6 | 12 |
| Not Hispanic or Latino | 136 | 134 | 270 |
| Race/Ethnicity, Customized(Participants) | Xeomin Short Flex | Xeomin Long Flex | Total |
|---|---|---|---|
| White | 130 | 128 | 258 |
| Black or African American | 7 | 7 | 14 |
| Asian | 1 | 1 | 2 |
| American Indian or Alaska Native | 2 | 1 | 3 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 1 |
| Other | 2 | 2 | 4 |
| Region of Enrollment(Participants) | Xeomin Short Flex | Xeomin Long Flex | Total |
|---|---|---|---|
| United States | 142 | 140 | 282 |
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merz Pharmaceuticals GmbH